La Jolla Pharmaceutical (LJPC) Stock Rating Lowered by ValuEngine

La Jolla Pharmaceutical (NASDAQ:LJPC) was downgraded by ValuEngine from a “buy” rating to a “hold” rating in a report issued on Friday.

LJPC has been the subject of a number of other research reports. HC Wainwright reissued a “buy” rating and issued a $83.00 price objective (up previously from $72.00) on shares of La Jolla Pharmaceutical in a report on Friday, May 11th. BidaskClub raised shares of La Jolla Pharmaceutical from a “sell” rating to a “hold” rating in a report on Tuesday, March 13th. Zacks Investment Research raised shares of La Jolla Pharmaceutical from a “sell” rating to a “hold” rating in a report on Tuesday, April 17th. Finally, Chardan Capital reissued a “buy” rating and issued a $115.00 price objective on shares of La Jolla Pharmaceutical in a report on Monday, June 18th. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $58.00.

La Jolla Pharmaceutical traded down $0.11, reaching $29.17, during trading on Friday, according to Marketbeat. The company’s stock had a trading volume of 288,043 shares, compared to its average volume of 469,390. The company has a market capitalization of $757.69 million, a P/E ratio of -5.39 and a beta of 1.40. La Jolla Pharmaceutical has a 12 month low of $22.68 and a 12 month high of $41.36.

La Jolla Pharmaceutical (NASDAQ:LJPC) last posted its quarterly earnings data on Thursday, May 10th. The biopharmaceutical company reported ($2.22) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.48) by ($0.74). The business had revenue of $0.81 million for the quarter. research analysts forecast that La Jolla Pharmaceutical will post -7.32 earnings per share for the current fiscal year.

Institutional investors have recently modified their holdings of the company. SG Americas Securities LLC bought a new stake in shares of La Jolla Pharmaceutical during the 1st quarter worth approximately $134,000. Silvant Capital Management LLC bought a new stake in shares of La Jolla Pharmaceutical during the 1st quarter worth approximately $189,000. MetLife Investment Advisors LLC bought a new stake in shares of La Jolla Pharmaceutical during the 4th quarter worth approximately $276,000. WINTON GROUP Ltd bought a new stake in shares of La Jolla Pharmaceutical during the 1st quarter worth approximately $276,000. Finally, LPL Financial LLC bought a new stake in shares of La Jolla Pharmaceutical during the 4th quarter worth approximately $434,000.

About La Jolla Pharmaceutical

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. It offers GIAPREZA, an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for La Jolla Pharmaceutical (NASDAQ:LJPC)

Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply